Immunomodulation for Recurrent Respiratory Tract Infections: New Insights and Perspectives

A narrative summary of presentations from the ‘Immunomodulation: New Insights and Perspectives’ symposium held at the 1st World Association for Infectious Disease and Immunological Disorders (WAidid), Milan, Italy, 18th–20th February 2016

*Susanna Esposito,1 Michael Roth2

1. Paediatric Highly Intensive Care Unit, Fondazione IRCCS Ca’ Granda Maggiore Policlinico Hospital, University of Milan, Milan, Italy
2. Department of Pulmonary Cell Research and Pneumology, University Hospital of Basel, Basel, Switzerland
*Correspondence to

Disclosure: The authors received an honorarium from OM/Vifor Pharma (Meyrin, Switzerland) as international experts and presenters at the ‘Immunomodulation: New Insights and Perspectives’ symposium held at the first WAidid, Milan, Italy.
Acknowledgements: Writing assistance was provided by Dr Ewen Legg of Halcyon Medical Writing.
Support: The publication of this article was funded by OM/Vifor Pharma. The views and opinions expressed are those of the authors and not necessarily those of OM/Vifor Pharma.
Citation: EMJ Respir. 2016;4[Suppl 10]:2-10

Meeting Summary

The 1st biennial WAidid Congress held in Milan, Italy, brought together academics and clinicians from the broad field of infectious diseases and immunology. The conference was founded in order to create a network connecting this diverse field and to allow the showcasing of data and therapeutic techniques amongst specialists concentrating on different age groups and organs. Prof Roth and Conference Chair Prof Esposito presented a symposium on the use of immunomodulation for prophylaxis against recurrent respiratory tract infections on Day 2 of the conference.

The symposium covered risk factors in the paediatric population and different treatment options for recurrent respiratory tract infections before focussing on the immunomodulatory prophylactic OM-85 (Broncho-Vaxom®, Broncho-Munal®, Ommunal®, Paxoral®, Vaxoral®). OM-85 is an orally administered immunomodulator, which has been shown to provide protection against respiratory infections of both viral and bacterial aetiologies in patients at high risk of recurrent infection. The symposium detailed the immunological mechanism of OM-85’s protective effects as well as safety and efficacy data in various patient populations.

Download (PDF, 137KB)

Comments are closed.